# US 2022/0031845 A1 · Diluents for compositions of cannabinoids and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0031845 A1
- Document ID: US20220031845A1
- Status: Published application
- Kind: A1
- Application number: 17/502,468
- Filed: 2021-10-15
- Published: 2022-02-03
- Earliest claimed: 2019-04-18
- Assignees: Kanabo Research Ltd.
- Applicants: Kanabo Research Ltd.
- Inventors: Avihu TAMIR; Michael ADDA
- Web page: https://patentgrep.com/patent/US20220031845A1

## CPC

- A61K 31/045: Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 9/0073: {Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy; (nasal sprays A61K9/0043; inhalation of vapours of volatile or heated drugs, e.g. essential oils or nicotine, A61K9/007; devices A61M)}
- A61K 31/105: Persulfides (thiuram disulfides A61K31/145; thiosulfonic acids A61K31/185)
- A61K 31/465: Nicotine; Derivatives thereof
- A61K 31/658: {o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol}
- A61K 36/3482: {Cannabis}
- A61M 16/021: {operated by electrical means (A61M16/202 – A61M16/205 take precedence)}
- A61P 25/26: Psychostimulants, e.g. nicotine, cocaine
- A61P 25/34: Tobacco-abuse
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides a stock compositions comprising a combinations of terpenes, that, when used as diluents in vaporizable formulations comprising cannabinoids, confer administration of reproducible constant dose of the formulations and its components such as cannabinoids, reduce throat irritation and improve the flavor of said formulations. The invention further provides vaporizable formulations comprising defined concentrations of the diluent(s) and cannabinoids. Use of the vaporizable formulations is provided as well.

## Claims

### Claim 1

A vaporizable formulation comprising (i) a cannabinoid, (ii) from 0.5 to 10 wt % of nicotine, and (iii) at least one diluent, wherein the cannabinoid is selected from CBD, CBDA or a combination thereof.

### Claim 2 (depends on 1)

The vaporizable formulation according to claim 1, wherein the least one diluent has a boiling point of at least 140° C., at least 200° C., at least 290° C. or at least 350° C.

### Claim 3 (depends on 1)

The vaporizable formulation according to claim 1, wherein the least one diluent is selected from the group consisting of natural bisabolol, sesquiterpenes, diterpenes, medium chain triglycerides (MCT), glyceryl trioctanoate, glyceryl tridecanoate, squalane, triethyl citrate, PEG and any combination thereof.

### Claim 4 (depends on 1)

The vaporizable formulation according to claim 1, comprising from 50 to 90 wt % of the diluent.

### Claim 5 (depends on 4)

The vaporizable formulation according to claim 4, wherein the diluent is (C8-C12) medium chain triglycerides.

### Claim 6 (depends on 5)

The vaporizable formulation according to claim 5, wherein the diluent is glyceryl trioctanoate.

### Claim 7 (depends on 4)

The vaporizable formulation according to claim 4, comprising from 5 to 25 wt % of the cannabinoid.

### Claim 8 (depends on 1)

The vaporizable formulation according to claim 1, comprising from 5 to 50 wt % of the diluent.

### Claim 9 (depends on 1)

The vaporizable formulation according to claim 1, comprising from 5 to 20 wt % of the diluent.

### Claim 10 (depends on 8)

The vaporizable formulation according to claim 8, wherein the diluent is natural bisabolol.

### Claim 11 (depends on 8)

The vaporizable formulation according to claim 8, comprising from 50 to 90 wt % of the cannabinoid.

### Claim 12 (depends on 1)

The vaporizable formulation according to claim 1, wherein the cannabinoid is CBD.

### Claim 13 (depends on 1)

The vaporizable formulation according to claim 1, wherein the cannabinoid is a combination of CBD and CBDA.

### Claim 14 (depends on 13)

The vaporizable formulation according to claim 13, wherein the molar ratio of CBD to CBDA is from 5:1 to 1:5, from 2:1 to 2:1 or about 1:1.

### Claim 15 (depends on 1)

The vaporizable formulation according to claim 1, comprising from 1 to 4 wt % of nicotine.

### Claim 16 (depends on 1)

The vaporizable formulation according to claim 1, comprising (i) from 60 to 80 wt % of the cannabinoid from 5 to 20 wt % of natural bisabolol, and from 1 to 4 wt % of nicotine, (i) from 50 to 70 wt % of the cannabinoid from 20 to 40 wt % of natural bisabolol, and from 1 to 4 wt % of nicotine, (ii) from 10 to 30 wt % of the cannabinoid, from 60 to 90 wt % of (C8-C12) medium chain triglycerides (MCT), and from 1 to 4 wt % of nicotine, or (iii) from 10 to 30 wt % of the cannabinoid, from 60 to 90 wt % of glyceryl trioctanoate, and from 1 to 4 wt % of nicotine, wherein the cannabinoid is selected from CBD and a combination of CBD and CBDA.

### Claim 17 (depends on 16)

The vaporizable formulation according to claim 16, wherein the molar ratio of CBD to CBDA is from 2:1 to 1:2 or about 1:1

### Claim 18 (depends on 1)

A method of treating a nicotine and/or tobacco smoking addiction in a subject in need thereof comprising administering the vaporizable formulation according to claim 1.
